Hair loss research roadmap
A cautious timeline of technologies and trials that could improve hair loss treatment by the end of this decade.
JAK Inhibitors
FDA approves baricitinib and ritlecitinib for alopecia areata, first systemic treatments ever approved for the condition.
Exosome Therapies
Multiple clinics begin offering exosome-based scalp injections. Early trial data shows promise for androgenetic alopecia with an effect size comparable to PRP.
Stem Cell & Cloning Trials
Phase I trials underway for follicle stem cell transplantation. Stemson Therapeutics completes first human safety study for iPSC-derived hair follicles.
CRISPR for DHT Sensitivity
First-in-human CRISPR trials targeting the androgen receptor gene in follicle dermal papilla cells begun in South Korea. Phase 1 safety data anticipated.
Follicle Multiplication
If Phase II data holds, follicle multiplication via in-vitro expansion of dermal papilla cells could enter Phase III trials with regulatory approval in sight.
Combination Biologics
A Wnt pathway activator or exosome product with acceptable safety profile could reach regulatory submission. Combination protocols being optimised.
Personalised Protocols
Gene therapy, biologics, and energy device combinations personalised by genetic profile. Clascoterone and pyrilutamide likely commercially available.
Better Treatment Combinations
For pattern hair loss, the realistic target is stronger combinations, better patient selection, and more durable maintenance. Full reversal is possible for some people but should not be presented as guaranteed or universal.
This roadmap is maintained from published trial data, regulatory filings, company updates, and primary research. It is not a guarantee of any specific outcome.